The interference with the Nrf2 pathway has been identified as one of the mechanisms of action of the Bcl-2 inhibitor venetoclax, which is currently used for the treatment of AML patients who are not eligible for intensive induction chemotherapy in combination with hypomethylating agents. Here, BCL2 is linked to acute myeloid leukemia.